Allergic Diseases as a Clinical Phenotype Marker in Patients with Common Variable Immunodeficiency

Basit Öğe Kaydı
dc.contributor.authorYildiz, Eray
dc.contributor.authorColkesen, Fatih
dc.contributor.authorArslan, Sevket
dc.contributor.authorEvcen, Recep
dc.contributor.authorAykan, Filiz Sadi
dc.contributor.authorKilinc, Mehmet
dc.date.accessioned2024-02-23T14:26:41Z
dc.date.available2024-02-23T14:26:41Z
dc.date.issued2023
dc.departmentNEÜen_US
dc.description.abstractIntroduction: Patients with common variable immunodeficiency (CVID) have been shown to be more predisposed to develop allergic diseases because of mucosal immune defects and immune dysregulation. The aim of this study was to determine the prevalence, and clinical and laboratory characteristics of various allergic diseases in patients with CVID. Methods: The study included patients aged & GE;18 years who were followed up for a diagnosis of CVID. Patients were separated into 5 groups according to the clinical phenotypic characteristics of lymphoproliferation, autoimmunity, gastrointestinal diseases, allergic diseases, and malignancy. Atopic dermatitis (AD), drug hypersensitivity reaction (DHR), allergic rhinitis (AR), and asthma were accepted as allergic diseases. Results: The most commonly seen clinical phenotypes were lymphoproliferation in 41 (48.8%) patients and allergic diseases in 31 (37%). AD was determined in 2 (2.4%) patient, DHR in 5 (6%), AR in 7 (8.3%), and asthma in 21 (25%). The delay in diagnosis of patients with allergic disease was determined to be shorter compared to those without allergic disease (p = 0.042). Serum total immunoglobulin E level, CD19(+) B cell, switched memory B cell, and natural killer cell counts were determined to be higher in the CVID patients with allergic disease compared to those without (p = 0.007, p = 0.022, p = 0.023, p = 0.017, respectively). Conclusion: Allergic diseases should be considered as a marker of clinical phenotype in CVID because of the clinical and immunological differences. Early diagnosis and treatment of allergic diseases in patients with CVID can improve quality of life.en_US
dc.identifier.doi10.1159/000530901
dc.identifier.endpage1055en_US
dc.identifier.issn1018-2438
dc.identifier.issn1423-0097
dc.identifier.issue10en_US
dc.identifier.pmid37473738en_US
dc.identifier.scopus2-s2.0-85168697339en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1047en_US
dc.identifier.urihttps://doi.org/10.1159/000530901
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14294
dc.identifier.volume184en_US
dc.identifier.wosWOS:001034059100001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofInternational Archives Of Allergy And Immunologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCommon Variable Immunodeficiencyen_US
dc.subjectClinical Phenotypingen_US
dc.subjectAllergic Diseasesen_US
dc.subjectAsthmaen_US
dc.subjectAllergic Rhinitisen_US
dc.titleAllergic Diseases as a Clinical Phenotype Marker in Patients with Common Variable Immunodeficiencyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu